|
Estrogen receptor β and TMPRSS2-ERG expression association with clinical outcomes in metastatic hormone-sensitive prostate cancer. |
|
|
Speakers' Bureau - AstraZeneca Spain; Janssen; MSD |
Research Funding - Janssen |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Speakers' Bureau - Kyowa Kirin; Pfizer |
Travel, Accommodations, Expenses - Kyowa Kirin; Pfizer |
|
|
Consulting or Advisory Role - Bristol-Myers Squibb |
Travel, Accommodations, Expenses - Ipsen; Pfizer |
|
Leonardo Rodriguez-Carunchio |
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Astellas Amgen BioPharama; AstraZeneca Spain; Ipsen; Janssen; Roche; Sanofi |
Research Funding - Astellas Amgen BioPharama; AstraZeneca Spain; Pierre Fabre |
Travel, Accommodations, Expenses - Janssen; Roche; Sanofi |
|
|
Consulting or Advisory Role - Astellas Oncology; AstraZeneca Spain; Bayer; Bristol-Myers Squibb; Clovis Oncology; Janssen Oncology; MSD; Pfizer; Roche; Sanofi |
Research Funding - Merck; Pfizer; Takeda |
|
Montserrat Domenech-Santasusana |
Consulting or Advisory Role - Sanofi |
Speakers' Bureau - Bristol-Myers Squibb; Pfizer |
Travel, Accommodations, Expenses - Lilly; Sanofi |
|
|
Consulting or Advisory Role - Ipsen; Pfizer |
Travel, Accommodations, Expenses - Merck |
|
Miguel Angel Climent Duran |
Honoraria - Astellas Pharma; Bayer; Bristol-Myers Squibb; EUSA Pharma; Ipsen; Janssen; Merck; Novartis; Pfizer; Pierre Fabre; Roche; Sanofi |
Consulting or Advisory Role - Astellas Pharma; Bayer; Bayer; Bristol-Myers Squibb; Celgene; Eisai; EUSA Pharma; Janssen Oncology; Janssen-Cilag; Merck; MSD Oncology; Pfizer; Roche/Genentech; Sanofi |
Travel, Accommodations, Expenses - Ipsen; Janssen; Merck; Pfizer; Roche |
|
|
Consulting or Advisory Role - AstraZeneca Spain; Bristol-Myers Squibb; GlaxoSmithKline; Janssen; Merck; Pfizer; Roche; Tesaro |
Research Funding - Janssen; Pfizer |
|
|
Consulting or Advisory Role - Astellas Amgen BioPharama; AstraZeneca Spain; Bayer; Janssen; Novartis; Sanofi Aventis GmbH |
Travel, Accommodations, Expenses - Janssen; Novartis Pharmaceuticals UK Ltd.; Sanofi |
|
|
Honoraria - Kyowa Kirin; Leo Pharma; Novartis; Pierre Fabre |
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Kyowa Kirin; MSD; Pfizer; ROVI |
|
Enrique Gonzalez -Billalabeitia |
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Advanced Accelerator Applications/Novartis; Astellas Pharma; AstraZéneca; Bayer; Bristol-Myers Squibb; Johnson & Johnson/Janssen; MSD Oncology; Pfizer; Roche; Sanofi |
Speakers' Bureau - Astellas Pharma; Bayer; Johnson & Johnson |
Research Funding - AB Science (Inst); Aragon Pharmaceuticals (Inst); Arog (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); AVEO (Inst); Bayer (Inst); Blueprint Medicines (Inst); BN ImmunoTherapeutics (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb International Corporation (BMS) (Inst); Clovis Oncology (Inst); Cougar Biotechnology (Inst); Deciphera; Exelixis (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Janssen-Cilag International NV (Inst); Karyopharm Therapeutics (Inst); Laboratories Leurquin Mediolanum (Inst); Lilly (Inst); Medimmune (Inst); Millenium Pharamceuticals (Inst); Nanobiotix (Inst); Novartis Farmacéutica SA (Inst); Pfizer (Inst); Puma Biotechnology (Inst); Roche (Inst); Sanofi Aventis GmbH (Inst); SFJ Pharmaceuticals Group (Inst); Teva (Inst) |
Travel, Accommodations, Expenses - AstraZeneca; BMS; Ipsen; Roche |
|
|
Consulting or Advisory Role - Astellas Pharma; Bristol-Myers Squibb; Eisai; EUSA Pharma; Ipsen; Merck Sharp & Dohme; Pfizer |
Speakers' Bureau - AstraZeneca; Bristol-Myers Squibb; Ipsen; Merck Sharp & Dohme; Pfizer; Roche/Genentech |
Research Funding - AB Science (Inst); Arog (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); AVEO (Inst); Bayer (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Clovis Oncology (Inst); Cougar Biotechnology (Inst); Deciphera (Inst); Exelixis (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Janssen Oncology (Inst); Karyopharm Therapeutics (Inst); MedImmune (Inst); Millennium (Inst); Nanobiotix (Inst); Novartis (Inst); Pfizer (Inst); Puma Biotechnology (Inst); Roche/Genentech (Inst); SFJ Pharmaceuticals Group (Inst); Teva (Inst) |
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Ipsen; Roche |
|
|
Employment - Novartis (I) |
Stock and Other Ownership Interests - Reveal Genomics |
Honoraria - Amgen; Daiichi Sankyo; Guardant Health; Lilly; MSD Oncology; Novartis; Pfizer; Roche |
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo; NanoString Technologies (Inst); Novartis; Oncolytics; Pfizer; Puma Biotechnology; Roche |
Research Funding - Incyte (Inst); Novartis (Inst); Puma Biotechnology (Inst); Roche (Inst) |
Patents, Royalties, Other Intellectual Property - HER2DX filing; METHODS FOR BREAST CANCER TREATMENT AND PREDICTION OF THERAPEUTIC RESPONSE (US 63/023785); PCT/EP2016/080056: HER2 AS A PREDICTOR OF RESPONSE TO DUAL HER2 BLOCKADE IN THE ABSENCE OF CYTOTOXIC THERAPY; WO/2018/096191. Chemoendocrine score (CES) Based on PAM50 for breast cancer with positive hormone receptors with an intermediate risk of recurrence |
Travel, Accommodations, Expenses - Daiichi Sankyo |
Other Relationship - Oncolytics; Peptomyc |
|
|
Speakers' Bureau - Astellas Amgen BioPharama; Bristol-Myers Squibb; Janssen; Novartis; Pfizer; Roche; Sanofi |
Research Funding - Bayer; Janssen; Pfizer/Calithera; Roche |
Travel, Accommodations, Expenses - Janssen; Pfizer |